Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. Show more

Life Science & Technology Park, Miami, FL, 33136, United States

Biotechnology

Healthcare

Market Cap

20.97M

52 Wk Range

$0.47 - $1.80

Previous Close

$0.67

Open

$0.68

Volume

600,083

Day Range

$0.67 - $0.75

Enterprise Value

6.163M

Cash

15.76M

Avg Qtr Burn

-4.37M

Insider Ownership

10.37%

Institutional Own.

9.92%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Lomecel-B (laromestrocel) Details Hypoplastic Left Heart Syndrome	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B (laromestrocel) Details Pediatric Dilated Cardiomyopathy (DCM)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B (laromestrocel) Details Alzheimer's disease	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B Details Aging Frailty	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lomecel-B Details Acute respiratory distress syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.